Patient Safety
Effective Date: May 13, 2026 · Last Revised: November 12, 2026
If you are experiencing a life-threatening reaction: call 911 immediately. This page tells you how to report non-emergency side effects and quality concerns to TelePeptide Health and, independently, to the U.S. FDA.
Your Treating Clinician
Please tell us about any side effect, adverse reaction, allergic response, suspected medication quality issue, or unexpected outcome associated with a TelePeptide Health program or medication, including issues that started after you stopped a medication. We want to hear from you whether the event seemed minor or serious, and whether you are sure the medication caused it or not. For LIFE-THREATENING SYMPTOMS (severe chest pain, trouble breathing, severe abdominal pain that does not stop, signs of a severe allergic reaction such as facial swelling or throat tightness, or loss of consciousness) CALL 911 or go to the nearest emergency room IMMEDIATELY. Do not wait to contact TelePeptide.
You can report to TelePeptide in the following ways. Clinical follow-up is provided by your treating clinician with our contracted medical group, Lone Star Virtual Health PLLC. (a) Patient account: if you enrolled through the TelePep store, sign in to your patient account there to contact your treating clinician directly. This is the main way to reach your clinician and the right place to describe what happened, when it started, and what you have done so far. (b) Phone: (201) 449-3080: if no one answers, leave a voicemail with your name and the best callback number. (c) Email: ahmed@telepeptide.org. Please include only your name, your contact details, and the medication involved: keep other health details out of email. We will help connect you with your treating clinician. If a report involves the quality of a dispensed medication, we will, with your permission, also share it with the dispensing pharmacy named on your label so it can update its own records.
You also have the right to report directly to the U.S. Food and Drug Administration through the MedWatch Adverse Event Reporting Program. Reports help the FDA identify safety signals for both FDA-approved drugs and compounded medications. Online: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program By phone: 1-800-FDA-1088 (1-800-332-1088) By fax: 1-800-FDA-0178 By mail: MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20857 You may file a MedWatch report independently of, before, or after notifying TelePeptide. We encourage patients with serious or unusual events to file both reports; this contributes to the wider safety surveillance system that protects everyone.
If you suspect a medication you received, compounded or not, is contaminated, mislabeled, the wrong strength, or otherwise defective, stop using it immediately and contact the dispensing pharmacy named on your label, with photos of the vial, label, and packaging if possible, and let us know at ahmed@telepeptide.org (your name, contact details, and the medication involved are enough). Save the medication for evaluation; do not discard it until the pharmacy or your clinician has advised next steps. You may also report compounded-drug quality issues directly to: - Your state Board of Pharmacy (which licenses 503A pharmacies) - The FDA, which oversees 503B outsourcing facilities, through MedWatch (contact information above) For a brand-name or generic medication, you may report a quality problem to FDA MedWatch (contact information above) or to its manufacturer.
Every report we receive is acknowledged, and we will help connect you with your treating clinician with our contracted medical group, who determines clinical follow-up. Depending on severity: (a) we may ask clarifying questions; (b) your prescribing clinician decides on clinical follow-up; (c) with your permission, we contact the dispensing pharmacy if a quality issue is suspected; (d) your clinician may recommend stopping or adjusting the medication if clinically indicated; (e) your clinician documents the event in your medical record; and (f) your clinician or the dispensing pharmacy may report the event to FDA MedWatch. We will never charge you for reporting a side effect.
Reports you send to TelePeptide are handled under our Privacy Policy at /privacy-policy; clinical documentation of the event is created and held by the contracted medical group under its own HIPAA Notice of Privacy Practices (see /privacy-practices). To keep health details out of email, report through your patient account where you can. We do not share patient-identified reports with the pharmacy or the FDA without your authorization, except as required by law for serious or life-threatening events. You will never be charged, billed, dropped from a program, or otherwise penalized for reporting a side effect or quality concern: full stop.
Compounded tirzepatide (a GIP/GLP-1 receptor agonist) commonly causes nausea, vomiting, diarrhea, constipation, indigestion, decreased appetite, headache, and fatigue. Less commonly, gallbladder issues, pancreatitis, kidney problems, and injection-site reactions. FDA-approved tirzepatide carries a boxed warning: in rodents it caused thyroid C-cell tumors, and it is not known whether it causes these tumors, including medullary thyroid carcinoma (MTC), in people; it must not be used by anyone with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Several other GLP-1 medications carry the same boxed warning, and it should be treated as applying to compounded GLP-1 medications too. Sermorelin troches (sermorelin is a GHRH analog) can cause headache, flushing, dizziness, and transient elevations in growth hormone. NAD+ injections may cause flushing, brief nausea, or injection-site soreness. Any compounded preparation may have additional risks that your clinician will discuss with you at the time of prescribing. For every treatment, including any not named above, product-specific information is given by your prescribing clinician and in the pharmacy labeling. This list is not exhaustive. The full informed consent at /medical-consent contains additional risk information. Always discuss risks with your prescribing clinician before starting or changing a medication.
Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Compounded medications dispensed through TelePeptide are prepared by licensed US compounding pharmacies. Because compounded products are not subject to the same post-market surveillance as FDA-approved drugs, patient-reported adverse events are especially important for identifying quality and safety issues. Your report matters.
TelePeptide Health · 2077 Center Ave, Fort Lee, NJ 07024 · ahmed@telepeptide.org